GSK Rings In More Change As CFO Heads For Exit In 2019
GlaxoSmithKline Plc, the maker of Sensodyne toothpaste and Panadol paracetamol, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.
The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. As his departure is voluntary he will not receive any severance payment.
GSK said it planned to look both internally and externally to identify a successor.
Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.
Walmsley, who took over in April 2017, has already appointed a new head of pharmaceuticals in Luke Miels and a new head of drug research in Hal Barron, as well as making Karenann Terrell head of digital operations, an area within Dingemans's orbit.
Dingemans said he believed he was leaving GSK at a time when it had established "strong foundations" to deliver improved financial performance.